ライフサイエンスコーパス: RNA level

1 genes (DNA level) or trans-splicing events (RNA level).

2 suggesting a fairly broad expression at the RNA level.

3 ifies genomically encoded nucleotides at the RNA level.

4 ed differences among HIV-infected persons by RNA level.

5 effectors of SIE at the protein but not the RNA level.

6 me to HCV RNA detection was dependent on HCV RNA level.

7 by reprogramming genetic information at the RNA level.

8 ter or higher and an undetectable plasma HIV RNA level.

9 el, HIV infection, CD4 cell count, and HIV-1 RNA level.

10 erapeutics and biomarkers at the protein and RNA level.

11 opportunities for manipulating cells at the RNA level.

12 ement insertions by splicing them out at the RNA level.

13 culated from the trajectory of ZEB messenger RNA level.

14 els, more advanced WHO stage, and higher HIV RNA levels.

15 taining CARD domain (Asc) at the protein and RNA levels.

16 tissue displayed increased TANGO1 messenger RNA levels.

17 40) promoter and globally decreased cellular RNA levels.

18 ral therapy (ART) and suppressed blood HIV-1 RNA levels.

19 ent of JAG1 without affecting Jag1 messenger RNA levels.

20 n could all be suppressed by manipulating U7 RNA levels.

21 mice and corresponded to a decrease in hGH1 RNA levels.

22 weeks; P = .008) due to lower baseline HIV-1 RNA levels.

23 semen and blood samples were assayed for HCV RNA levels.

24 mulative up-regulation of target protein and RNA levels.

25 vealed that SRSF1 did not affect oncoprotein RNA levels.

26 retroviral therapy or to have suppressed HIV RNA levels.

27 among different drugs and related to CSF HIV RNA levels.

28 n after stimulation, prior to peak messenger RNA levels.

29 ncy affects protein abundance independent of RNA levels.

30 l processes in shaping mitochondrial-encoded RNA levels.

31 deficiency, without affecting mitochondrial RNA levels.

32 ine comprehensive effects of Li treatment on RNA levels.

33 low-up) to document true care status and HIV RNA levels.

34 cline in expression in cells with high viral RNA levels.

35 virus to pathogenic Nef-OPEN and plasma SIV RNA levels.

36 strongly correlate with each other and with RNA levels.

37 d had lower HIV RNA levels (median log10 HIV RNA level, 1.59 vs 4.08 and 3.83, respectively; P < .01)

38 s for at least 6 months and had plasma HIV-1 RNA levels 1000-200 000 copies/mL.

39 The plasma HIV-1 RNA level 12 weeks after treatment interruption was comp

40 proportion of patients with undetectable HCV-RNA levels 12 weeks after therapy completion (SVR12).

41 HIV RNA levels 51-1000 copies/mL were less frequently observ

42 Three patients had undetectable HCV RNA levels 76 weeks after a single dose of RG-101.

43 io also had higher NAIP and PYCARD messenger RNA levels after lipopolysaccharide stimulation, suggest

44 of Mcl-1 expression at both the protein and RNA levels, along with a subsequent increase in apoptosi

45 Hepatitis E virus RNA levels also remained detectable in the serum and sto

46 ur study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the

47 Increased Gas5 RNA level and decreased miR-222 expression were shown in

48 eased hematopoietic factors at the messenger RNA level and decreased secretion of factors at the prot

49 This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESR

50 Lower intrahepatic HBV pregenomic RNA levels and 25 predictive genes were identified in IF

51 e is mediated by restoration of steady-state RNA levels and consequent rebalancing of translational h

52 related with adipose interleukin-6 messenger RNA levels and fat mass (p < 0.001; R = 0.64 and 0.89).

53 as measured by both steady-state and nascent RNA levels and perturbed embryonic stem cell differentia

54 The effects of CDK9 inhibition on RNA levels and protein expression, apoptosis induction,

55 striking changes in QKI-dependent messenger RNA levels and splicing of RNA transcripts.

56 ate local human immunodeficiency virus (HIV) RNA levels and the risk of sexual HIV transmission.

57 ween plasma and CSF, lower overall CSF HIV-1 RNA level, and longer ART duration, among others (model

58 sed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time bet

59 cell reprogramming, globally increases m(6)A RNA levels, and enhances m(6)A modification of the Nanog

60 sion molecules, chemokine/chemokine receptor RNA levels, and infiltration of leukocytes including mac

61 ctoderm progenitor cells increased lncRHOXF1 RNA levels, and siRNA-mediated disruption of lncRHOXF1 d

62 ays enable RNA processing, the regulation of RNA levels, and the surveillance of aberrant or poorly f

63 fection, with higher DNA and cell-associated RNA levels, and with lower expression of multiple anti-H

64 ariables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy regimen) were investig

65 Mutant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, surpris

66 biogenesis, we found that Laccase2 circular RNA levels are not controlled by Mbl or the Laccase2 gen

67 o not, in general, correlate well, messenger RNA levels are used as convenient proxies for protein le

68 transplantation among patients with this HCV-RNA level at their last measurement before transplantati

69 f peginterferon + ribavirin dependent on HCV RNA level at week 12; (2) Harvoni treatment, 12 weeks; (

70 The decline of HBV RNA levels at months 3 and 6 of treatment was to be the

71 This readout is highly sensitive to small RNA levels at the source, allowing plasticity in the pos

72 ften does not correlate with EGFR protein or RNA levels because they do not reflect delivery to the c

73 he primary efficacy end point was SVR12 (HCV RNA level below the lower limit of quantification at pos

74 tic patients, respectively, had baseline HCV RNA levels below 4M and 6M IU/mL with ART.

75 ed virological response (SVR)-defined as HCV RNA levels below a designated threshold of quantificatio

76 Sixty-three percent had HCV RNA levels below the lower limit of quantification at we

77 of TIA-1 and TIAR affected ZIKV protein and RNA levels but not viral titers.

78 utant ABCA4 RNA levels approximated WT ABCA4 RNA levels but, surprisingly, only trace amounts of muta

79 LA-C expression is modulated not just at the RNA level, but also at the protein level.

80 Adjustment for latest HIV RNA level, but not for CD4 cell count or cancer risk fac

81 primary T-ALL cases with high GLI1 messenger RNA levels, but not those with low or undetectable GLI1

82 a large set of elements that function at the RNA level by interacting with RBPs.

83 xide and itraconazole reduced GLI1 messenger RNA levels by 75% from baseline (P < .001).

84 We show that miR-122 enhances HCV RNA levels by altering the fraction of HCV genomes avail

85 imbalance is achieved through rescue of MRP RNA levels by ectopic expression.

86 While perturbation of RNA levels by Li has been previously reported, its effec

87 human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 particip

88 sequence of this precise regulation of viral RNA levels by PGC1alpha is a subtle increase in cytoplas

89 Qk translation confirms that Qk5 controls Qk RNA levels by promoting accumulation and alternative spl

90 change in patients who had undetectable HCV RNA levels by week 8 post-RG-101 injection.

91 o their capsid protein genes, namely, at the RNA level, by regulating the essential splicing of an in

92 It is now clear that modulation of circular RNA levels can result in a variety of molecular and phys

93 We compared HIV RNA levels, CD4 counts and percentages, lipids, and grow

94 ding was not significantly influenced by HIV RNA levels, CD4+ cell counts, or antiretroviral therapy.

95 polyamide demonstrated a global decrease in RNA levels consistent with inhibition of transcription.

96 Elevated seminal HCV RNA levels could contribute to sexual transmission of HC

97 Analyses of proviral and viral RNA levels demonstrate that PLVA fitness is severely res

98 Lithium's modification of RNA levels depends on both RNA length and type.

99 RNA levels detected at steady state are the consequence

100 The index patient had high EBOV RNA levels, developed respiratory and renal failure requ

101 Despite having undetectable HIV RNA levels during cART, men with higher concentrations o

102 sed claudin-7 mRNA and nascent heteronuclear RNA levels during differentiation.

103 fic processes that appeared to change at the RNA level (e.g., ribosome biogenesis) did not do so at t

104 few differences between F and A cells at the RNA level either under baseline conditions or after trea

105 ular interactions, both at the chromatin and RNA level, exhibit remarkable specificity for the regula

106 On the RNA level, expanded (CUG)n repeats form hairpin structur

107 model that incorporates these protein/DNA or RNA level fluctuations can effectively predict antigenic

108 c-exposed monkeys, we found higher messenger RNA levels for 1) most NF-kappaB family members, 2) all

109 s with 13 potently and durably decreased HCV RNA levels for gt1a, gt2a, and gt3a.

110 analysis reveals limited overall changes in RNA levels for RNA Pol II genes after TbRH2A loss, but i

111 ns and PARN-depleted cells exhibited reduced RNA levels for several key genes that are associated wit

112 y end point was the mean change in the HIV-1 RNA level from day 1 through day 8 in the randomized coh

113 lyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who experienced virologic f

114 gene copy number is altered experimentally, RNA levels generally scale accordingly.

115 h specificity, and good correlation with HCV RNA levels greater than 3000 IU/mL and have the potentia

116 RCHITECT, HCVcAg correlated closely with HCV RNA levels greater than 3000 IU/mL.

117 In Lusaka Province, HIV RNA levels greater than or equal to 1,000 copies/ml were

118 Patients with HCV-RNA levels >/= 12 IU ml-1 after 4 weeks of treatment ach

119 er, 32 genes differentially expressed at the RNA level had concomitant differential expression of the

120 Adjustment for latest HIV RNA level had little impact on the protective effect of

121 -MB-231, which has the highest xCT messenger RNA level, had the highest tracer uptake (P = 0.0058 whe

122 >/=6 months before screening) and plasma HCV RNA levels higher than 10,000 IU/mL.

123 ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment,

124 ir/peak CD4+ T-cell count (CD4) and/or HIV-1 RNA level (HIV RNA) best predict anal cancer risk.

125 he collective impact of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and i

126 also replicated acutely to high peak plasma RNA levels identical to those for SIVmac239 and caused o

127 d cells increased both cyclin B1 protein and RNA levels, implicating FoxM1 as a critical target for c

128 Results were validated at the RNA level in an independent cohort and at the protein le

129 cute HCV and HIV coinfection, the median HCV RNA level in blood specimens from those with seminal HCV

130 The median HCV RNA level in blood was 4.0 log IU/mL higher than that in

131 ) assay, we identified 25 SNPs that affected RNA levels in a consistent manner in two neuroblastoma c

132 We further demonstrate that MYCN messenger RNA levels in amplified disease are exceptionally high a

133 light the need for cells to maintain poly(A)-RNA levels in balance with PABPs and other RBPs with mut

134 ZIKV RNA levels in blood and tissues were significantly highe

135 Ebola viral RNA levels in blood peaked at a median of 7 days after t

136 FOXO3 and PERK expression at the protein and RNA levels in breast cancer patient samples.

137 Using a single-copy assay, we measured HIV-1 RNA levels in CSF and plasma specimens from 220 HIV-posi

138 The relationship between HAND, lower HIV-1 RNA levels in CSF, and lower CD4(+) T-cell counts may re

139 Mitochondrial RNA levels in general were found to be lowest in activel

140 3 h half-life and a robust decrease in viral RNA levels in HCV-infected patients, thereby validating

141 Next, we found that PPM1F messenger RNA levels in human blood were downregulated in cases wi

142 d adoptive T cell transfer did not alter LAT RNA levels in LTalpha(-/-) infected mice.

143 after excluding people with undetectable HIV RNA levels in non-transmitters.

144 after excluding people with undetectable HIV RNA levels in nontransmitters.

145 essed in the context of viral blips or viral RNA levels in peripheral blood or gastrointestinal biops

146 Surprisingly, the alterations in messenger RNA levels in septic cardiomyopathy were both distinct f

147 s infection was indicated by increased viral RNA levels in the brains of RNase L(-/-) mice.

148 rall effect on cell-associated HIV-1 DNA and RNA levels in the entire cohort, participants who mainta

149 and more profound than changes in messenger RNA levels in the hearts of patients with end-stage hear

150 reduced Ser-235 phosphorylation and the HCV RNA levels in the infected cells.

151 genes with significantly decreased messenger RNA levels in the mutant mouse cortex are involved in my

152 Quantification of TMC6 and TMC8 RNA levels in various organs revealed that lymphoid tiss

153 human immunodeficiency virus type 1 (HIV-1) RNA levels in women are lower early in untreated HIV-1 i

154 Correlates of higher CSF HIV-1 RNA levels included higher nadir and current CD4(+) T-ce

155 omic and epigenetic alterations, (ii) at the RNA level including differential mRNA splicing and stabi

156 evels (by 1.98 log10 copies/mL), whereas HBV RNA levels increased (by 0.47 log10 copies/mL; P < .05).

157 ted that RTA targets MyD88 expression at the RNA level, inhibits RNA synthesis of MyD88, and may bind

158 t with simeprevir or daclatasvir reduced HCV RNA levels initially, but the levels later rebounded.

159 els in each tissue and how they compare with RNA levels is important for understanding human biology

160 ght correlation between gene copy number and RNA levels is not observed in recently isolated wild Sac

161 ulation consisted of 43 patients who had HCV-RNA level less than 25 IU/mL at the time of transplantat

162 acy was measured by SVR12, defined as an HCV-RNA level less than 25 IU/mL.

163 s or the proportion of participants with HIV RNA level less than 50 copies/mL.

164 oint was the proportion of patients with HCV-RNA levels less than 25 IU/mL at 12 weeks after transpla

165 ighly active antiretroviral therapy with HIV RNA levels less than 400 copies/mL was associated with p

166 At 48 weeks, 90% of patients achieved HIV-1 RNA levels less than 50 copies/mL.

167 ssociated with low CD4 cell counts, high HIV RNA levels, low CD4/CD8 ratios, and prior AIDS.

168 ts with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment.

169 ltrasensitive assays on specimens with HIV-1 RNA level <400 copies/mL at weeks 24, 48, and 104 reveal

170 IV suppression status (defined as HIV type 1 RNA level <400 copies/mL for >90% of follow-up time) was

171 als were eligible if they had a plasma HIV-1 RNA level <50 copies/mL for at least 2 years on a stable

172 PHIVs were on ART, with HIV-1 RNA level <=400 copies/mL.

173 Despite years of plasma HIV-RNA levels <40 copies per milliliter during combination

174 ents with prolonged viral suppression of HIV-RNA levels <40 copies per milliliter for more than 6 y.

175 ral therapy (cART) with suppression of HIV-1 RNA levels <40 copies/mL.

176 Participants with plasma HIV RNA levels <50 copies/mL during antiretroviral therapy a

177 ve, non-cirrhotic patients with baseline HCV RNA levels <6 million IU/mL (6.8 log10 IU/mL).

178 PHIV were on ART, with HIV-1 RNA levels <=400 copies/mL.

179 The extracted DNA exhibited acceptable RNA levels (<10% contamination), functionality in polyme

180 At week 48, a virologic response (HIV-1 RNA level, <40 copies per milliliter) had occurred in 54

181 ipheral CD4+ T-cell-associated HIV-1 DNA and RNA levels, lymphocyte activation, viral population stru

182 Serum HBV RNA levels may serve as a novel tool for prediction of s

183 s, respectively; P < .01), and had lower HIV RNA levels (median log10 HIV RNA level, 1.59 vs 4.08 and

184 reduced the levels of cyclin B1 protein, and RNA levels normally increased in response to DNA-damagin

185 rrect for the known inaccuracy of plasma HIV RNA levels obtained from DBSs.

186 , or after 4 weeks if no 2-log10 drop in HCV RNA level occurs, promises rapid HCV elimination.

187 current CD4(+) T-cell counts, a plasma HIV-1 RNA level of >/= 1 copy/mL, and a lower central nervous

188 tiretroviral treatment, 73% had plasma a HIV RNA level of <50 copies/mL, and the median CD4(+) T-cell

189 e of HIV-positive participants with an HIV-1 RNA level of 400 copies per milliliter or less in the in

190 percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week

191 At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was foun

192 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter.

193 CAMK2 (CAMKII), we examined blood messenger RNA level of CAMK2G in humans and found it to be lower i

194 aled a significant decrease in the messenger RNA level of early B cell factor 1 (EBF1) and paired box

195 percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as dete

196 Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16

197 An HIV-1 RNA level of less than 50 copies per milliliter at week

198 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84%

199 rates of DBS in participants with plasma HIV RNA levels of >/=35 copies/ml and 100% detection rates o

200 rates of DPS in participants with plasma HIV RNA levels of >/=394 copies/ml.

201 ere observed with respect to detecting HIV-1 RNA levels of >50 copies/ml and identifying VF at the 50

202 additional participants with confirmed HIV-1 RNA levels of >50 copies/ml during trial follow-up were

203 .82), Abbott was more likely to detect HIV-1 RNA levels of >50 copies/ml than Monitor (matched-pair o

204 ive, noncirrhotic patients with baseline HCV RNA levels of <4 or <6 million (M) IU/mL based on post-h

205 t limit of detection equivalent to serum HCV RNA levels of 150-250 IU/mL; using nondenaturation of se

206 I, 0.1 to 0.5]), but HAART in those with HIV RNA levels of 400 copies/mL or greater was not.

207 the HCV-Ags EIA were equivalent to serum HCV RNA levels of approximate 150-250 IU/mL.

208 r their association with residual cognition: RNA levels of both UNC5C (estimated effect = -0.40, 95%

209 In the presence of comparable messenger RNA levels of CD3, IL-10, TGFbeta, IL2, IFNgamma, and IL

210 hat were associated with increased messenger RNA levels of CSF1 in the PFC.

211 more M. tuberculosis, which expressed higher RNA levels of genes required for M. tuberculosis surviva

212 infection significantly decreased prostasin RNA levels of in vivo and in vitro models.

213 absorbed labeled fatty acids, and messenger RNA levels of Lgr5(+) stem cell markers (Lgr5, Olfm4, Sm

214 ic antisense oligonucleotides to inhibit the RNA levels of mutant AR in the central nervous system (C

215 Transcriptome analysis shows diminished RNA levels of numerous genes in Nfatc1 (-/-) CD8(+) T ce

216 s, Malanchi and colleagues analyze messenger RNA levels of periostin (POSTN) in pulmonary fibroblasts

217 ued the anxiety-like phenotype and messenger RNA levels of Ppm1f in amygdala and mPFC in male mice an

218 lpha displayed ROS accumulation, had reduced RNA levels of proteins involved in ROS detoxification, a

219 RNA levels of QSOX1, PLBD1, and S100A8 on admission with

220 primary outcome was the change in messenger RNA levels of the GLI family zinc finger 1 (GLI1) gene (

221 a1 increased the protein expression, but not RNA levels, of both DNMT1 and DNMT3a.

222 d increased nuclear RNA, with polyadenylated RNA levels only elevated after prolonged stress or reoxy

223 IFNgamma decreased viral RNA levels only in dAP7 cells and synergized with antibo

224 er EREG or AREG in top tertile for messenger RNA level) or "low expressor" (neither EREG nor AREG in

225 p17 were significantly associated with HIV-1 RNA levels (P < .001); Ab levels to gp160 (P < .001) and

226 negative correlation between DDX5 messenger RNA levels, pluripotency gene expression, and liver tumo

227 s of transcriptome-wide changes in messenger RNA levels provoked by various types of oxidative stress

228 endent approaches by monitoring steady-state RNA levels, rates of RNA synthesis, transcription initia

229 knockdown (80% at the protein and messenger RNA levels) reduced by 30% cytokine-induced apoptosis an

230 ells of these EC/VCs had lower ccr2 and ccr5 RNA levels, reduced CCR2 and CCR5 cell-surface expressio

231 -term NA treatment of patients with CHB, HBV RNA levels remained higher than HBV DNA levels.

232 However, the RALY's role in regulating RNA levels remains elusive.

233 Clinical recovery, EBOV RNA level, resolution of Ebola viremia, survival with di

234 study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the prenylation

235 or absence of HCV RNA or changes in the HCV RNA level should be taken into consideration for therapy

236 f exonic mutations and overexpression at the RNA level suggested a transcriptional and/or posttranscr

237 3L rescues the effect of PARN depletion on Y RNA levels, suggesting that PARN stabilizes Y RNAs by re

238 significantly greater decrease in the HIV-1 RNA level than those who received placebo during the fir

239 th HCV+SS had significantly higher serum HCV-RNA levels than patients with HCV-negative SS (6.28 [IQR

240 th HCV+SS had significantly higher serum HCV-RNA levels than patients with HCV-negative SS (6.28 IQR

241 reliable indicator of variations in cellular RNA levels, that better correlates with cellular metabol

242 d a consistent (but small) increase in viral RNA levels, the drb4 mutant correlated with a less prono

243 Next, from single-cell, single-RNA level time-lapse microscopy of independent lineages

244 n found in the sequence corresponding at the RNA level to functional domains of the 5' UTR, could als

245 he importance of controlling 5'-triphosphate RNA levels to prevent aberrant RIG-I signaling and demon

246 Although variation in RNA levels, transcription factor binding, and chromatin

247 While F9 is fused to Alb at the DNA and RNA levels, two separate proteins are synthesized by way

248 2 months of therapy had significantly lower RNA levels up to 6 months after the cessation of study d

249 HBV RNA levels vary significantly from those of established

250 Furthermore, HIF-1alpha messenger RNA levels vary significantly within CLL patients and co

251 A high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-

252 ived antiretroviral therapy and had an HIV-1 RNA level (viral load) of at least 1000 copies per milli

253 At day 8, the mean decrease in the HIV-1 RNA level was 0.79 log(10) copies per milliliter in the

254 kPa; cirrhosis, n = 9); median baseline HCV-RNA level was 1.38 x 10(6) IU/mL.

255 gative patients, a lower baseline plasma HBV RNA level was independently associated with response to

256 Peak HCV RNA level was lower during reinfection than primary infe

257 viduals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease

258 A corresponding decrease in NPPA messenger RNA levels was also observed at both time points.

259 A similar decline in HBV RNA levels was observed in HBeAg-negative patients.

260 tern of elevated NF-kappaB-related messenger RNA levels was seen in adult mice that received daily po

261 HIV serostatus and plasma HIV RNA level were measured annually at multidisease health

262 Reduction of endogenous ATXN1 messenger RNA levels were >/=30% in the deep cerebellar nuclei, th

263 (n = 20) HIV infection were studied once HIV RNA levels were <50 copies/mL for >/= 6 months.

264 Increased CSF1 messenger RNA levels were also detected in the postmortem dorsolat

265 Higher baseline HIV-1 RNA levels were associated with greater gains in periphe

266 Higher HIV RNA levels were associated with higher IL-6 levels, and

267 Patients with low and high HCV RNA levels were at higher risk of ESRD than those who we

268 Viral RNA levels were below limits of detection during all oth

269 HCV RNA levels were correlated in semen and blood (r(2) = 0.

270 MicroRNA and messenger RNA levels were determined by quantitative real-time pol

271 The PBMCs alpha7 messenger RNA levels were determined by real-time quantitative rev

272 HBV RNA levels were determined in serial serum samples from

273 vated protein kinase phosphatase-1 messenger RNA levels were down-regulated.

274 By 14 days p.i., spliced SIV RNA levels were high in all tissues, but they were the h

275 Hdac4 messenger RNA levels were higher in the amygdala 2 h after tone-sh

276 s of EVG, TDF, TAF, tenofovir (TFV), and HIV RNA levels were measured at baseline and week 24.

277 Finally, higher tissue factor messenger RNA levels were measured in the whole blood of 131RR don

278 riants of PPARGC1A and protein and messenger RNA levels were measured.

279 ymptoms and developed moderate illness; EBOV RNA levels were moderate, and both patients recovered.

280 The decreases in occupancy and RNA levels were not seen, however, during the dark (acti

281 Plasma HIV-1 RNA levels were not significantly lower in early-treated

282 beta-mediated antiviral state, ExoN(-) viral RNA levels were not substantially reduced relative to th

283 or-beta, but not -alpha intragraft messenger RNA levels were reduced and capillary protein localizati

284 e type I interferon (IFN-I) response, as VA1 RNA levels were reduced by pretreatment of Caco-2 cells

285 In contrast, CDC42 and PAK1 messenger RNA levels were significantly downregulated specifically

286 HCV RNA levels were significantly higher with CAP/CTM than w

287 4, LIMK1, LIMK2, ARHGDIA, and PAK3 messenger RNA levels were significantly upregulated in subjects wi

288 anti-CD3/CD28 mAbs, virion-associated HIV-1 RNA levels were similar between TCM and TN cells (15 135

289 cleavage/polyadenylation machinery, circular RNA levels were similarly increased.

290 CA HIV-1 DNA and RNA levels were strongly correlated (r= 0.77 to 1;P= 0.0

291 of patients with active replication, but HCV RNA levels were substantially lower than in serum specim

292 t 7 days postinoculation (p.i.), spliced SIV RNA levels were the highest in the genital lymph nodes,

293 AC6 messenger RNA levels were the highest of all 9 membrane-bound AC i

294 reating genetic disease, particularly at the RNA level, where disease-relevant sequences can be rescu

295 nother layer of epigenetic regulation at the RNA level, where mRNA is subjected to chemical modificat

296 d to a >10,000-fold reduction in Orsay virus RNA levels, which could be rescued by ectopic expression

297 NA levels and HIV DNA decay and cellular HIV RNA levels, while adjusting for peak HIV RNA, nadir CD4(

298 ivators at the protein level, but not at the RNA level, with profound implications for understanding

299 act as potent regulators of translation and RNA levels, with a similar magnitude to miRNAs.

300 d nasal swabs were collected to quantify HCV-RNA levels within rectal and nasal fluids.